001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
05. November 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results
25. Oktober 2021 16:01 ET | Delcath Systems, Inc.
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at Upcoming Virtual Investor Conferences
02. September 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Announces Second Quarter 2021 Results
10. August 2021 07:30 ET | Delcath Systems, Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
09. August 2021 07:30 ET | Delcath Systems, Inc.
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at Upcoming Virtual Investor Conferences
05. August 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results
28. Juli 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET
07. Juli 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Set to Join Russell Microcap® Index
08. Juni 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is...
001_Delcath_CorporateLogo_Tagline.png
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting
07. Juni 2021 07:30 ET | Delcath Systems, Inc.
As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data...